Info

ImmunoGen, Inc. is focused on the development of antibody-based anticancer therapeutics. The Company’s Tumor-Activated Prodrug (TAP) technology uses antibodies to deliver a potent cytotoxic agent specifically to cancer cells. The antibody component enables a TAP compound to bind specifically to cancer cells that express a particular target antigen and the cytotoxic agent serves to kill the cancer cell. Its TAP technology is designed to enable the creation of anticancer products. The Company’s TAP technology can be used with antibodies that have anticancer activity of their own to create compounds with enhanced anticancer activity. In addition, its TAP technology can be used with antibodies that lack anticancer activity. The Company developed its cell-killing agents specifically for antibody-directed delivery to cancer targets. The Company has developed alternative maytansinoid cell-killing agents (such as DM1 and DM4) and linkers.(Source: 10-K)